Advertisement

Classification of rheumatoid arthritis

  • Daniel Aletaha
Chapter

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approximately 1% of the adult population [1]. Although there is no cure, patients may reach a state of remission, which has become an achievable goal with optimal early treatment. Early intervention in particular has made RA a less disabling disease and if treatment is instituted right from the onset, no functional impairment may occur and structural integrity may be preserved (Figures 1.1 and 1.2) [2]. Over the past decade, early intensive treatment has also been proven to change the course of later RA [2,3], and therefore, the treatment goal should be to treat RA early and persistently until remission is present [4,5].

Keywords

Rheumatoid Arthritis Rheumatoid Factor Lyme Disease Acute Phase Response European League 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 suppl):1-12.Google Scholar
  2. 2.
    Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906-914.Google Scholar
  3. 3.
    Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347-356.Google Scholar
  4. 4.
    Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.Google Scholar
  5. 5.
    Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.Google Scholar
  6. 6.
    Hazlewood G, Aletaha D, Carmona L, et al. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J Rheumatol Suppl. 2011;87:54-58.Google Scholar
  7. 7.
    Aletaha D, Huizinga TW. The use of data from early arthritis clinics for clinical research. Best Pract Res Clin Rheumatol. 2009;23:117-123.Google Scholar
  8. 8.
    Funovits J, Aletaha D, Bykerk V, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010;69:1589-1595.Google Scholar
  9. 9.
    Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62:2582-2591.Google Scholar
  10. 10.
    Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-1588.Google Scholar

Copyright information

© Springer Healthcare 2015

Authors and Affiliations

  • Daniel Aletaha
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineMedical University of ViennaViennaAustria

Personalised recommendations